These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10348778)

  • 21. Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection.
    Campbell LA; Kuo CC; Suchland RJ; Rothstein DM
    Antimicrob Agents Chemother; 2008 May; 52(5):1855-8. PubMed ID: 18332169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the management of Chlamydia pneumoniae infections.
    Hammerschlag MR
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):493-503. PubMed ID: 15482145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of therapy with antibiotics on lipid metabolism and antioxidant reserve of patients with ischemic heart disease during Chlamydia pneumoniae infection].
    Klochkov VA; Dovgalevskiĭ PIa; Umetskiĭ KS; Chalyk NE; Ansimova OM; Zigangirova NA; Petiaev I
    Kardiologiia; 2005; 45(12):58-61. PubMed ID: 16353050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
    Anderson JL; Muhlestein JB; Carlquist J; Allen A; Trehan S; Nielson C; Hall S; Brady J; Egger M; Horne B; Lim T
    Circulation; 1999 Mar; 99(12):1540-7. PubMed ID: 10096928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Establishment and experimental study on mouse model of Chlamydia pneumoniae pneumonitis].
    Shi Y; Yin J; Zhan H
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Oct; 24(10):592-5. PubMed ID: 11770419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease.
    Gupta S
    Am Heart J; 1999 Nov; 138(5 Pt 2):S539-41. PubMed ID: 10539869
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diagnosis and therapy of Chlamydia pneumoniae and trachomatis].
    Freidank H
    Internist (Berl); 1997 Oct; 38(10):995-6. PubMed ID: 9432510
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Chlamydia pneumoniae.
    Hammerschlag MR
    Int J Antimicrob Agents; 2000 Aug; 15(3):239, 241. PubMed ID: 10926449
    [No Abstract]   [Full Text] [Related]  

  • 29. The pathogenesis of Chlamydia pneumoniae-type pneumonitis in mice.
    Shi Y; Yin J; Zhan H; Feng G; Zhang X; Su X; Song Y; Xia X; Zhou X; Shen P
    Chin Med J (Engl); 2003 Mar; 116(3):328-32. PubMed ID: 12781030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Chlamydia pneumoniae reinfection accelerates the development of insulin resistance and diabetes in obese C57BL/6 mice.
    Wang C; Gao D; Kaltenboeck B
    J Infect Dis; 2009 Jul; 200(2):279-87. PubMed ID: 19508161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.
    Dreses-Werringloer U; Padubrin I; Zeidler H; Köhler L
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3001-8. PubMed ID: 11600348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.
    Jackson LA; Stewart DK; Wang SP; Cooke DB; Cantrell T; Grayston JT
    J Antimicrob Chemother; 1999 Sep; 44(3):411-4. PubMed ID: 10511413
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Kohlhoff SA; Huerta N; Hammerschlag MR
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines.
    Mueller M; Postius S; Thimm JG; Gueinzius K; Muehldorfer I; Hermann C
    Immunobiology; 2004; 209(8):599-608. PubMed ID: 15638128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlamydia pneumoniae and acute coronary syndrome.
    Mitchell WM; Stratton CW
    N Engl J Med; 2005 Aug; 353(5):525-8; author reply 525-8. PubMed ID: 16080250
    [No Abstract]   [Full Text] [Related]  

  • 36. Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study.
    Kuzman I; Oresković K; Schönwald S; Culig J
    Int J Clin Pharmacol Res; 1996; 16(4-5):103-7. PubMed ID: 9172008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].
    Sáez-Llorens X; Castaño E; Wubbel L; Castrejón MM; de Morales I; Vallarino D; de Atencio I; Muñiz L; Olsen K; McCracken GH
    Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
    Hammerschlag MR; Reznik T; Roblin PM; Ramirez J; Summersgill J; Bukofzer S
    J Antimicrob Chemother; 2003 Apr; 51(4):1025-8. PubMed ID: 12654764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections.
    Rothstein DM; van Duzer J; Sternlicht A; Gilman SC
    Arch Pharm (Weinheim); 2007 Oct; 340(10):517-29. PubMed ID: 17912677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic approaches to Chlamydia infections.
    Senn L; Hammerschlag MR; Greub G
    Expert Opin Pharmacother; 2005 Oct; 6(13):2281-90. PubMed ID: 16218888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.